Cizzle Biotechnology Holdings PLC
LSE:CIZ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (2.6), the stock would be worth GBX-0.29 (111% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -24.2 | GBX2.75 |
0%
|
| Industry Average | 2.6 | GBX-0.29 |
-111%
|
| Country Average | 0.1 | GBX-0.01 |
-100%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Cizzle Biotechnology Holdings PLC
LSE:CIZ
|
10.9m GBP | -24.2 | -9.7 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
292.6B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 45 422.5 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
100.8B ZAR | 11.3 | 10.4 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
67.3B USD | -45 486.7 | 38 034.1 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
53B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
37.1B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
31.4B EUR | 20.6 | 175.7 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
34.4B USD | 40.1 | -3 148.5 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
29.6B ZAR | 9.8 | 6.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.1 |
| Median | 0.1 |
| 70th Percentile | 0.2 |
| Max | 2 143.8 |
Other Multiples
Cizzle Biotechnology Holdings PLC
Glance View
Cizzle Biotechnology Holdings Plc is a holding company, which is actively seeking for new investment opportunity. The Company’s proof-of-concept prototype test is based on the ability to detect a plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early stage lung cancer. The company helps to reduce the need for repeated computed tomography (CT) scanning. The firm provides its product AZD1656 is treatment for COVID19 patients. AZD1656 is an immunomodulator which damps down the inflammatory response characteristic of coronavirus disease (COVID-19) infection, while enhancing the part of the immune response.
